L-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells

Cancer Research

Volumn 75, Issue 2, 2015, Pages 275-283

  Fletcher, Matthew ^a   Ramirez, Maria E ^a   Sierra, Rosa A ^a   Raber, Patrick ^a   Thevenot, Paul ^a   Al Khami, Amir A ^a   Sanchez Pino, Dulfary ^a   Hernez, Claudia ^a   Wyczechowska, Dorota D ^a   Ochoa, Augusto C ^a   Rodriguez, Paulo C ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; ARGININE; BOVINE SERUM ALBUMIN; CITRULLINE; MACROGOL DERIVATIVE;

ADOPTIVE TRANSFER; AMINO ACID SYNTHESIS; ANAEROBIC GLYCOLYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL CYCLE PROGRESSION; CELL ENERGY; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME DEGRADATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MITOCHONDRIAL RESPIRATION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; STARVATION; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CARCINOMA, LEWIS LUNG; DEFICIENCY; DRUG EFFECTS; ENERGY METABOLISM; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM;

ANIMALS; ARGININE; CARCINOMA, LEWIS LUNG; ENERGY METABOLISM; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MYELOID CELLS; POLYETHYLENE GLYCOLS; T-LYMPHOCYTES;

EID: 84920939262     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1491     Document Type: Article

References (48)

1. Andersen MH. The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia 2014;28:1784-92.
2. Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science 2013;342:1242454.
3. Phillips MM, Sheaff MT, Szlosarek PW. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat 2013;45:251-62.
4. Szlosarek PW, Luong P, Phillips MM, Baccarini M, Stephen E, Szyszko T, et al. Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol 2013;31:e111-3.
5. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 2003;24:302-6.
6. Hernandez CP, Morrow K, Lopez-Barcons LA, Zabaleta J, Sierra R, Velasco C, et al. Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood 2010;115:5214-21.
7. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, et al. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007;67:309-17.
8. Lam TL, Wong GK, Chow HY, Chong HC, Chow TL, Kwok SY, et al. Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis. Pigment Cell Melanoma Res 2011;24:366-76.
9. Tsui SM, Lam WM, Lam TL, Chong HC, So PK, Kwok SY, et al. Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC). Cancer Cell Int 2009;9:9.
10. Agrawal V, Woo JH, Mauldin JP, Jo C, Stone EM, Georgiou G, et al. Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells. Anticancer Drugs 2012;23:51-64.
11. Morrow K, Hernandez CP, Raber P, Del VL, Wilk AM, Majumdar S, et al. Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia. Leukemia 2013;27:569-77.
12. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates Tlymphocyte cell-cycle progression. Blood 2007;109:1568-73.
13. Rodriguez PC, Hernandez CP, Morrow K, Sierra R, Zabaleta J, Wyczechowska DD, et al. L-arginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression. J Immunol 2010;185:5198-204.
14. Zea AH, Rodriguez PC, Culotta KS, Hernandez CP, DeSalvo J, Ochoa JB, et al. l-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol 2004;232:21-31.
15. Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 2010;116:5738-47.
16. Zhu X, Pribis JP, Rodriguez PC, Morris SM Jr., Vodovotz Y, Billiar TR, et al. The central role of arginine catabolismin T-cell dysfunction and increased susceptibility to infection after physical injury. Ann Surg 2014;259:171-8.
17. Chang CH, Curtis JD, Maggi LB Jr., Faubert B, Villarino AV, O'Sullivan D, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013;153:1239-51.
18. Gubser PM, Bantug GR, Razik L, Fischer M, Dimeloe S, Hoenger G, et al. Rapid effector function of memory CD8+ T cells requires an immediateearly glycolytic switch. Nat Immunol 2013;14:1064-72.
19. Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 2013;38:225-36.
20. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity 2013;38:633-43.
21. Green DR, Rathmell J. Sweet nothings: sensing of sugar metabolites controls T cell function. Cell Metab 2013;18:7-8.
22. Gabrilovich DI,Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
23. Raber P, Ochoa AC, Rodriguez PC. Metabolism of L-arginine by myeloidderived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 2012;41:614-34.
24. Peranzoni E, Marigo I, Dolcetti L, Ugel S, Sonda N, Taschin E, et al. Role of arginine metabolism in immunity and immunopathology. Immunobiology 2007;212:795-812.
25. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008;222:180-91.
26. Raber PL, Thevenot P, Sierra R, Wyczechowska D, Halle D, Ramirez ME, et al. Subpopulations of myeloid-derived suppressor cells (MDSC) impair T cell responses through independent nitric oxide-related pathways. Int J Cancer 2013;134:2853-64.
27. Guo G,Marrero L, Rodriguez P, Del VL, Ochoa A, Cui Y. Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid-like stromal network. Cancer Res 2013;73:1668-75.
28. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by maturemyeloid cells inhibits T-cell receptor expression and antigen-speci fic T-cell responses. Cancer Res 2004;64:5839-49.
29. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al.GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005;22:633-42.
30. Bunpo P, Dudley A, Cundiff JK, Cavener DR, Wek RC, Anthony TG. GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent L-asparaginase. J Biol Chem 2009;284:32742-9.
31. Hao S, Sharp JW, Ross-Inta CM, McDaniel BJ, Anthony TG, Wek RC, et al. Uncharged tRNA and sensing of amino acid deficiency in mammalian piriform cortex. Science 2005;307:1776-8.
32. Peng W, Robertson L, Gallinetti J, Mejia P, Vose S, Charlip A, et al. Surgical stress resistance induced by single amino acid deprivation requires Gcn2 in mice. Sci Transl Med 2012;4:118ra11.
33. Maurin AC, Jousse C, Averous J, Parry L, Bruhat A, Cherasse Y, et al. The GCN2 kinase biases feeding behavior tomaintain amino acid homeostasis in omnivores. Cell Metab 2005;1:273-7.
34. Yau T, Cheng PN, Chan P, Chan W, Chen L, Yuen J, et al. A phase 1 doseescalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest New Drugs 2013;31:99-107.
35. Dugan ME, Knabe DA, Wu G. The induction of citrulline synthesis from glutamine in enterocytes of weaned pigs is not due primarily to age or change in diet. J Nutr 1995;125:2388-93.
36. Windmueller HG, Spaeth AE. Uptake and metabolism of plasma glutamine by the small intestine. J Biol Chem 1974;249:5070-9.
37. Windmueller HG. Glutamine utilization by the small intestine. Adv Enzymol Relat Areas Mol Biol 1982;53:201-37.
38. Houdijk AP, Rijnsburger ER, Jansen J, Wesdorp RI, Weiss JK, McCamish MA, et al. Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma. Lancet 1998;352:772-6.
39. Ligthart-Melis GC, van de Poll MC, Vermeulen MA, Boelens PG, van den Tol MP, van SC, et al. Enteral administration of alanyl-[2-(15)N]glutamine contributes more to the de novo synthesis of arginine than does intravenous infusion of the dipeptide in humans. Am J Clin Nutr 2009;90:95-105.
40. Mauldin JP, Zeinali I, Kleypas K, Woo JH, Blackwood RS, Jo CH, et al. Recombinant human arginase toxicity in mice is reduced by citrulline supplementation. Transl Oncol 2012;5:26-31.
41. Patejunas G, Bradley A, Beaudet AL, O'Brien WE. Generation of a mouse model for citrullinemia by targeted disruption of the argininosuccinate synthetase gene. Somat Cell Mol Genet 1994;20:55-60.
42. Qualls JE, Subramanian C, Rafi W, Smith AM, Balouzian L, DeFreitas AA, et al. Sustained generation of nitric oxide and control of mycobacterial infection requires argininosuccinate synthase 1. Cell Host Microbe 2012;12:313-23.
43. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009;9:900-9.
44. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010;70:3052-61.
45. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinibmediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.
46. Bunpo P, Cundiff JK, Reinert RB, Wek RC, Aldrich CJ, Anthony TG. The eIF2 kinase GCN2 is essential for the murine immune system to adapt to amino acid deprivation by asparaginase. J Nutr 2010;140:2020-27.
47. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumourderived lactic acid. Nature 2014;513:559-63.
48. Thevenot PT, Sierra RA, Raber PL, Al-Khami AA, Trillo-Tinoco J, Zarreii P, et al. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity 2014;41:389-401.